Neostigmine Versus Sugammadex on Renal Functions

Phase 4

Active, not recruiting

• Conditions: Sugammadex; Neostigmine
• Interventions: Drug: Sugammadex; Drug: Neostigmine

• Registration Number: NCT06081738
• Lead Sponsor: Menoufia University

Brief Summary

The study will assess the acute effects of sugammadex or neostigmine on renal function as determined with more specific and sensitive tests in laparoscopic cholecystectomy

Detailed Description

Not available

Study Timeline

• Study Start: 2023-03-01
• Primary Completion: 2023-09-01
• Study First Submitted: 2023-09-23
• Status Verified: 2023-10
• Study First Submitted QC: 2023-10-10
• Last Update Submitted: 2023-10-10
• Study First Posted: 2023-10-13
• Last Update Posted: 2023-10-13
• Study Completion: 2023-12-31

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: All
• Target Recruitment: 64

Inclusion Criteria

• normal renal function (serum Cr 0.4- 1.4 g/dL)
• American Society of Anesthesiologists (ASA) Class I-II

Exclusion Criteria

• Incapacity to consent.
• Pre-existing impaired kidney functions.
• Severe neuromuscular disease, as: myasthenia gravis & muscular dystrophy.
• Intra-operative bleeding
• Lengthy operations that exceed 2 hours.
• Hemodynamic changes more than 20% of the base line

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Sugammadex Group	Sugammadex	-
Neostigmine Group	Neostigmine	-

Primary Outcome Measures

Name	Time	Method
neutrophil gelatinase associated lipocalin (NGAL) values	baseline ( 2 days preoperative) and 12 hours after surgery	normal overall unisex value 47-55 ng/ml

Trial Locations

Locations (1)

Menoufia University Hospitals; 🇪🇬 Shibīn Al Kawm, Menoufia, Egypt